
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ESAIY | OTC Markets | USD | Delayed | |
4523 | Frankfurt | EUR | Delayed | |
4523 | Tokyo | JPY | Delayed |
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1); Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Methycobal for the treatment of peripheral neuropathy; Jyseleca, a janus kinase inhibitor; Goofice for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, treatment for dementia; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Haruo Naito | 76 | 1998 | CEO, Representative Corporate Officer & Director |
Fumihiko Ike | 71 | 2021 | Independent Outside Chairman |
Richard Thornley | 60 | 2022 | Outside Independent Director |
Toru Moriyama | 70 | 2023 | Outside Independent Director |
Takuji Kanai | 65 | 2024 | Independent Outside Director |
Yasushi Okada | 67 | 2025 | Director |
Ryota Miura | 51 | 2021 | Independent Outside Director |
Kenta Takahashi | 66 | 2015 | Director |
Hiroyuki Kato | 68 | 2022 | Director |
Yuko Yasuda | 64 | 2023 | Outside Independent Director |
Ryoko Ueda | 52 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review